Rivaroxaban halves major bleeds in EINSTEIN PE
This article was originally published in Scrip
Executive Summary
Bayer and Janssen's oral Factor Xa inhibitor rivaroxaban (Xarelto) is as effective as the standard of care for treating pulmonary embolism (PE) but with half the level of serious bleeding, data from the pivotal EINSTEIN PE study suggest.